SynthesisFrontiers in neurology2026
The efficacy and potential pharmacological mechanism of Fufang Danshen Tablet in promoting the rehabilitation of ischemic stroke: a meta-analysis and
Synthesis in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Fufang Danshen Tablet (FDT) is a traditional Chinese medicine (TCM) formula with remarkable efficacy in invigorating blood and eliminating blood stasis, thus commonly used in treating ischemic stroke. However, no systemic summary has been conducted to evaluate its efficacy yet. This study aims to determine the efficacy of FDT therapy for promoting the rehabilitation of ischemic stroke and to explore the potential pharmacological mechanism through an Methods: Eligible clinical trials involving FDT therapy for ischemic stroke were searched across nine online databases. Meta-analysis was conducted with RevMan and Stata software. Evaluation of the quality of evidence was performed on the GRADE system. Moreover, GEO datasets, network pharmacology, and molecular docking were employed to explore the potential pharmacological mechanism. Results: 29 clinical trials concerning 1,634 participants were incorporated into the present meta-analysis. Compared with usual care alone, FDT combined with usual care exerted better efficacy in individuals with ischemic stroke, as evidenced by an elevated overall response rate and decreased National Institute of Health Stroke Scale (NIHSS), as well as the improvement of hemorheology, inflammation, and lipid metabolism. Moreover, meta-analysis of FDT individual intervention trials also showed significant therapeutic effects. Further network pharmacology and molecular docking analysis emphasized the potentially important role of the AKT/GSK3β/Cyclin D1 pathway for FDT to regulate oligodendrocyte precursor cells (OPCs) in treating ischemic stroke. Conclusion: FDT appears to significantly enhance neurological recovery, promote blood circulation, inhibit the inflammatory cascade, and lower blood lipid levels in patients with ischemic stroke. The AKT/GSK3β/Cyclin D1 pathway was predicted to be a potential mechanism of FDT in intervening ischemic stroke. In the future, more long-term follow-up RCTs with high quality are urgently needed, as well as experimental validations for the pharmacological mechanism. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251015475, CRD420251015475.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.